Sanofi Employees Protest Planned Sale of Amilly Factory

Workers at the Loiret site express concerns over job security and long-term viability as Sanofi plans to sell the facility to Astrea Pharma.

Sanofi announced plans to sell its Amilly factory, which produces Aspegic and Kardegic, to Astrea Pharma, citing a strategic shift toward innovative medicines.
The sale, expected to finalize by autumn 2025, includes commitments to maintain all 276 jobs and continue production for up to ten years.
Workers, representing 70-80% of the factory's employees, have been staging daily strikes since March 5, escalating their protests to weekly rotating walkouts.
Unions and employees express doubts about Astrea Pharma's financial stability, fearing potential liquidation and job losses within a few years.
Syndicates and local officials are urging government intervention to ensure the factory's long-term operations and safeguard domestic production of critical medicines.